November 29, 2017 MENLO PARK, Calif.--(BUSINESS WIRE)--Today, GE introduced Drawbridge Health, a privately-held healthcare technology company focused on enabling personal diagnostic testing — anytime, anywhere. Drawbridge Health is developing proprietary technology designed to integrate draw, collection and sample stabilization into a single device.

Healthcare providers will be able to deliver a superior patient experience, eliminating the need for phlebotomy and travel to blood draw centers. This integrated technology is also being developed to support room temperature shipping and streamlined downstream processing, ensuring reliable, accurate results. Through this integration of engineering and proprietary chemistry, Drawbridge Health is developing a people-friendly system for drawing and stabilizing blood samples.

The Drawbridge solution is being designed to offer a way for healthcare providers and diagnostic testing companies to better engage their patient-consumers and help enable them to manage their own health — driving a shift from reacting to tracking. By introducing a simple, comfortable blood draw solution, Drawbridge Health can alter the market for patients and healthcare providers by broadening the availability and access for molecular tests for a variety of diseases, as well as providing a convenient way to monitor overall health, therapy response and disease progression.

“At GE we share technology, markets, structure and knowledge across our varied businesses, which uniquely positions us to tackle many issues, including this one,” said Risa Stack, Managing Director of New Business Creation, GE Ventures. “With Drawbridge Health, we are combining technology from GE Global Research, expertise from GE Healthcare and business models from GE Ventures to offer a simple, safe and more efficient solution that can help save time, money and lives.”

Lee McCracken joined Drawbridge Health as Chief Executive Officer and the company’s Board of Directors, bringing more than 25 years of experience developing and growing businesses across the biotech, pharma and diagnostics sectors. Previously, he served as CEO of Gensignia Life Sciences, a molecular diagnostics company focused on the early detection of lung cancer through the integration of miRNA biology and digital health algorithms. Lee holds a BS in Commerce from Santa Clara University, a Master of Computer Science from the University of Dayton and an MBA from the Anderson School of Management at UCLA.

Business Affairs Homepage